No Data
No Data
Maxim Group Upgrades Brainstorm Cell Therapeutics(BCLI.US) to Buy Rating, Announces Target Price $2
Maxim Group analyst Jason McCarthy upgrades $Brainstorm Cell Therapeutics(BCLI.US)$ to a buy rating, and sets the target price at $2.According to TipRanks data, the analyst has a success rate of 24.0%
Optimistic Buy Rating for Brainstorm Cell Therapeutics as NurOwn Advances Into Enhanced Phase 3b ALS Trial
Brainstorm Cell Therptcs Price Target Announced at $2.00/Share by Maxim Group
Brainstorm Cell Therptcs Price Target Announced at $2.00/Share by Maxim
Express News | Maxim Group Upgrades Brainstorm Cell to Buy, Announces $2 Price Target
Brainstorm Cell Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 455.56% Maxim Group → $2 Upgrades Hold → Buy 09/28/2023 — Maxim Group Downgrades Buy → Hold 03
Express News | Brainstorm Cell Therapeutics Inc : Maxim Group Raises to Buy From Hold
FattyChick : If this hits $2, im a millionaire.![undefined undefined](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)